

Rho-kinase: important new therapeutic target in cardiovascular diseases

Kimio Satoh, Yoshihiro Fukumoto, and Hiroaki Shimokawa

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Submitted 1 April 2011; accepted in final form 21 May 2011

Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. *Am J Physiol Heart Circ Physiol* 301: H287–H296, 2011. First published May 27, 2011; doi:10.1152/ajpheart.00327.2011.— Rho-kinase (ROCKs) belongs to the family of serine/threonine kinases and is an important downstream effector of the small GTP-binding protein RhoA. There are two isoforms of Rho-kinase, ROCK1 and ROCK2, and they have different functions with ROCK1 for circulating inflammatory cells and ROCK2 for vascular smooth muscle cells. It has been demonstrated that the RhoA/Rho-kinase pathway plays an important role in various fundamental cellular functions, including contraction, motility, proliferation, and apoptosis, leading to the development of cardiovascular disease. The important role of Rho-kinase in vivo has been demonstrated in the pathogenesis of vasospasm, arteriosclerosis, ischemia-reperfusion injury, hypertension, pulmonary hypertension, stroke, and heart failure. Furthermore, the beneficial effects of fasudil, a selective Rho-kinase inhibitor, have been demonstrated for the treatment of several cardiovascular diseases in humans. Thus the Rho-kinase pathway is an important new therapeutic target in cardiovascular medicine.

cyclophilin A; oxidative stress; inflammation

THE RHO FAMILY OF small G proteins comprises 20 members of ubiquitously expressed proteins in mammals, including RhoA, Rac1, and Cdc42 (25, 65, 122). Among them, RhoA is the best-characterized protein that acts as a molecular switch that cycles between an inactive GDP-bound and an active GTP-bound conformation, interacting with downstream targets to elicit a variety of cellular responses (Fig. 1) (23). The activity of RhoA is controlled by the guanine nucleotide exchange factors that catalyze the exchange of GDP for GTP (102). In contrast, GTPase-activating proteins stimulate the intrinsic GTPase activity and inactivate RhoA (12). It has been demonstrated that guanine nucleotide dissociation inhibitors block spontaneous RhoA activation (Fig. 1) (81).


In 1996, Rho-kinase (Rho-kinase- α /ROCK 2 and Rho-kinase- β /ROCK 1) was identified as the effector of Rho (Fig. 2) and has been extensively studied, especially on its functions in the cardiovascular system (6, 53). Phosphorylation of myosin light chain (MLC) is a key event in the regulation of vascular smooth muscle cell (VSMC) contraction. MLC is phosphorylated by Ca^{2+} -calmodulin-activated MLC kinase and dephosphorylated by MLC phosphatase. Agonists bind to G protein-coupled receptors and induce contraction by increasing both cytosolic Ca^{2+} concentration and Rho-kinase activity through mediating guanine nucleotide exchange factor. The substrates of Rho-kinase have been identified, including MLC, myosin-binding subunit or myosin phosphatase target subunit 1, ezrin/radixin/moesin family, adducin, phosphatase and tensin homolog on chromosome 10, and LIM-kinases (Fig. 1). Rho-kinase enhances MLC phosphorylation through the inhibition

of myosin-binding subunit of myosin phosphatase and mediates agonists-induced VSMC contraction (Fig. 1).

The interaction between endothelial cells (ECs) and VSMCs plays an important role in regulating vascular integrity and vascular homeostasis. ECs release vasoactive factors, such as prostacyclin, nitric oxide (NO), and endothelium-derived hyperpolarizing factor, participating in the regulation of vascular tone and arterial resistance (110, 118, 135). It has been demonstrated that both endothelial NO production and NO-mediated signaling in VSMCs are targets and effectors of the RhoA/Rho-kinase pathway. In ECs, the RhoA/Rho-kinase pathway negatively regulates NO production. In contrast, VSMCs are among the most plastic of all cells in their ability to respond to different stimuli. Growth factors secreted from VSMCs play an important role in mediating various cellular responses in vascular remodeling (10, 11, 30). Recent evidence suggests that many other stimuli that modulate VSMC functions, including reactive oxygen species (ROS), promote VSMC growth by inducing auto/paracrine growth mechanisms (127). Among those auto/paracrine factors, cyclophilin A (CyPA) has been identified as a ROS-related protein that is secreted from VSMCs by RhoA/Rho-kinase activation (95, 120) (Figs. 3 and 4). We have recently demonstrated that the extracellular CyPA decreases endothelial NO synthase (eNOS) expression (78), suggesting the indirect role of RhoA/Rho-kinase for the negative regulation of endothelial NO production. The initial investigations in our laboratory on the therapeutic importance of Rho-kinase were previously summarized (117). Since then, significant progress has been made in our knowledge on the therapeutic importance of Rho-kinase in cardiovascular medicine. In this article, we will briefly review the recent progress in the translational research on the

Address for reprint requests and other correspondence: H. Shimokawa, Dept. of Cardiovascular Medicine, Tohoku Univ. Graduate School of Medicine, Sendai, 980-8574, Japan (e-mail: shimo@cardio.med.tohoku.ac.jp).

Fig. 1. The Rho/Rho-kinase signaling pathway. Rho GTPases are small GTP-binding proteins that act as molecular switches and regulate many intracellular signaling pathways. RhoA cycles between an inactive GDP-bound and an active GTP-bound conformation, interacting with downstream targets, including Rho-kinase. The activity of RhoA is controlled by the guanine nucleotide exchange factors (GEFs) that catalyze exchange of GDP for GTP. GTPase-activating proteins (GAPs) stimulate the intrinsic GTPase activity and inactivate RhoA. Guanine nucleotide dissociation inhibitors (GDIs) block spontaneous RhoA activation. Various substrates of Rho-kinase have been identified, including myosin phosphatase target subunit 1 (MYPT-1), myosin light chain (MLC), ezrin/radixin/moesin (ERM) family, adducin, phosphatase and tensin homolog on chromosome 10 (PTEN), and LIM-kinases, etc. 5-HT, 5-hydroxytryptamine (serotonin); ET-1, endothelin-1; CRMP-2, collapsin response mediator protein 2; CPI-17, PKC-potentiated inhibitory protein 17; IP₃, inositol 1,4,5-trisphosphate; PAI-1, plasminogen activator inhibitor-1; MCP-1, monocyte chemoattractant protein-1.



therapeutic importance of the Rho-kinase pathway in cardiovascular medicine.


Role of Rho-Kinase in the Regulation of Cardiovascular Function

Rho-kinase is a serine/threonine kinase with a molecular mass of ~160 kDa. Two isoforms of Rho-kinase encoded by two different genes have been identified (Fig. 2) (58, 69, 75). In humans, ROCK1 (Rho-kinase-β) and ROCK2 (Rho-kinase-α) genes are located separately on chromosome 18 and chromosome 2, respectively. They are ubiquitously expressed in invertebrates and vertebrates with ROCK1, especially in circulating inflammatory cells and ROCK2 in VSMCs. ROCKs consist of three major domains, including a kinase domain in its NH₂-terminal domain, a coiled-coil domain that includes Rho-binding domain in its middle portion and a putative pleckstrin homology (PH) domain in its COOH-terminal domain (25) (Fig. 2). ROCKs activity is enhanced by binding of GTP-bound active form of RhoA (69) (Fig. 1). Rho-kinase inhibitors, fasudil (7) and Y-27632 (131), have been developed, and they inhibit Rho-kinase activity in a competitive manner with ATP at the Rho-binding site (19). It has been demonstrated that hydroxyfasudil, a major active metabolite

of fasudil, exerts a more specific inhibitory effect on Rho-kinase (37, 116).

Although the regulation of ROCK expression has not been fully elucidated, some studies have reported changes in ROCK expression. Functional differences between ROCK1 and ROCK2 have been reported; ROCK1 is specifically cleaved by caspase-3, whereas ROCK2 is cleaved by granzyme B (15, 104). The small G protein RhoE specially binds to the NH₂-terminal region of ROCK1 at the kinase domain (Fig. 2), whereas the myosin phosphatase target subunit 1 binds specially to ROCK2 (56, 139). RhoE binding to ROCK1 inhibits its activity and prevents RhoA binding to Rho-binding domain (85). Both ROCK1 and ROCK2 mRNAs and proteins are upregulated by angiotensin II (ANG II) via ANG II type 1 receptor stimulation and by interleukin-1β (IL-1β) (38). A number of Rho-kinase substrates have been identified (64) (Fig. 1), and Rho-kinase-mediated substrate phosphorylation causes actin filament formation, organization, and cytoskeleton rearrangement (Fig. 1) (86). The NH₂-terminal regions, upstream of the kinase domains of ROCKs, may play a role in determining substrate specificity of the two Rho-kinase isoforms (Fig. 2) (86).

Fig. 2. Molecular structures of Rho-kinase isoforms. There are 2 isoforms of Rho-kinase, ROCK1 and ROCK2, which consist of 3 major domains, including a kinase domain in its NH₂-terminal domain, a coiled-coil domain with Rho-binding domain in its middle portion and a putative pleckstrin homology (PH) domain in its COOH-terminal domain. ROCK1 and ROCK2 are highly homologous with an overall amino acid sequence identity of 65%.



The majority of Rho-kinase substrates have been identified *in vitro*. Thus ROCK1- and ROCK2-deficient mice have been generated to further elucidate the functions of the ROCK isoforms (108, 130). Importantly, ROCK1-deficient mice showed the eyelids opened at birth (108), whereas ROCK2-deficient mice showed placental dysfunction and fetal death (61, 79, 130, 146). Thus the role of ROCK2, the main isoform in the cardiovascular system, remains to be fully elucidated *in vivo*. To address this point, we have recently developed VSMC-specific ROCK2-deficient mice and found the crucial role of ROCK2 in the development of hypoxia-induced pulmonary hypertension (107). These mutant mice revealed normal growth and body weight under physiological conditions. However, chronic hypoxia significantly increased ROCK2 expression and ROCK activity in lung tissues from littermates, and the development of right ventricular systolic pressure and right ventricular hypertrophy induced by chronic hypoxia *in vivo* was evident in littermates but was suppressed in the VSMC-specific ROCK2-deficient mice. *In vitro*, the growth and migration of VSMCs were significantly reduced in ROCK2-deficient VSMCs compared with control VSMCs.

Rho-Kinase and Vascular Function

Rho-kinase has been implicated in the pathogenesis of cardiovascular disease, in part by promoting VSMC proliferation (4, 8, 82). Changes in the vascular redox state are a common pathway involved in the pathogenesis of atherosclerosis, aortic aneurysms, and vascular stenosis. Vascular ROS formation can be stimulated by mechanical stretch, pressure, shear stress, environmental factors (e.g., hypoxia), and growth factors (e.g., ANG II) (32). Importantly, Rho-kinase is substantially involved in the vascular effects of various vasoactive factors, including ANG II (28, 33, 37, 123), thrombin (103, 134), platelet-derived growth factor (54), extracellular nucleotides (99), and urotensin (100) (Fig. 1). It has been previously shown that statins enhance eNOS mRNA by cholesterol-independent mechanisms involving the inhibition of Rho geranylgeranyla-

tion (124). We have also demonstrated that statins and Rho-kinase inhibitors completely block the secretion of CyPA from VSMCs (93, 120). Rho-kinase plays an important role in mediating various cellular functions, not only VSMC contraction (109, 111) but also actin cytoskeleton organization (5, 34), adhesion, and cytokinesis (117). Thus Rho-kinase plays a crucial role for the development of cardiovascular disease through ROS production, inflammation, EC damage, and VSMC contraction and proliferation. Rho-kinase inhibitors have excellent vasodilator activity and can induce vasodilation when vasoconstrictor tone is increased by a variety of mechanisms, including the activation of G-coupled receptors-enhanced calcium entry, ventilatory hypoxia, NOS inhibition, and other mechanisms (14, 20, 21, 137).

Rho-Kinase, Inflammation, and Oxidative Stress

Rho-kinase augments inflammation by inducing proinflammatory molecules, including IL-6 (83), monocyte chemoattractant protein-1 (28), macrophage migration inhibitory factor (MIF) (35, 36), and sphingosine-1-phosphate (136). In ECs, Rho-kinase downregulates eNOS (125) and substantially activates proinflammatory pathways, including an enhanced expression of adhesion molecules. The expression of Rho-kinase is accelerated by inflammatory stimuli, such as ANG II and IL-1 β (38), and by a remnant lipoproteins in human coronary VSMCs (80). Rho-kinase also upregulates NAD(P)H oxidases (nox1, nox4, gp91^{phox}, and p22^{phox}) and augments ANG II-induced ROS production (37). Several growth factors are known to be secreted from VSMCs in response to oxidative stress. We have recently demonstrated that ROS activate a pathway containing vesicles that results in the secretion of CyPA (45, 120). Secreted extracellular CyPA stimulates ERK1/2, Akt, and JAK in VSMCs that contribute to ROS production and compose a vicious cycle for ROS augmentation (94, 97). CyPA is secreted from VSMCs via a highly regulated pathway that involves vesicle transport and plasma membrane binding (Fig. 3) (120). Rho GTPases, including RhoA, are key regulators in signaling pathways linked to actin cytoskeletal




Fig. 3. Rho-kinase and reactive oxygen species (ROS) production. Intracellular signaling pathways for Rho-kinase activation, ROS production, and cyclophilin A (CyPA) secretion are closely linked through vesicle-associated membrane protein 2 (VAMP2) vesicle formation. Secreted extracellular CyPA activates ERK1/2, Akt, and JAK, promoting ROS production and Rho-kinase activation again. VSMC, vascular smooth muscle cell.

rearrangement (66). RhoA plays a central role in vesicular trafficking pathways by controlling the organization of actin cytoskeleton. It has been reported that active participation of Rho GTPases is required for secretion. We showed that the expression of dominant-negative mutants of RhoA inhibited ROS-induced CyPA secretion, suggesting that RhoA-dependent signaling events regulate CyPA secretion (120). Myosin II is involved in the secretory mechanisms as a motor for vesicle transport (77). ROCKs, downstream effectors of RhoA, mediate myosin II activation via phosphorylation and inactivation of myosin II light chain phosphatase (53). We have also recently demonstrated that Rho-kinase inhibitor reduced ROS-induced CyPA secretion (95, 120) (Fig. 4). These results suggest that myosin II-mediated vesicle transport is required for CyPA secretion from VSMCs. CyPA is transported to the plasma membrane and colocalized with vesicle-associated membrane protein 2 in response to ROS stimulation (Fig. 3).

We demonstrated that extracellular CyPA stimulates proinflammatory signals in ECs, including the expression of E-selectin and vascular cell adhesion molecule-1 (44). In addition to the effects on vascular cells, CyPA has been shown to be a direct chemoattractant for inflammatory cells (16, 52), promoting matrix metalloproteinases (MMPs) activation (138, 144). All of these roles of CyPA derive from the activation of Rho-kinase in the cardiovascular system (Fig. 4). Recently, we have demonstrated that the extracellular CyPA activates Rho-kinase in human pulmonary VSMCs from patients with pulmonary hypertension (91). Thus CyPA may be a key mediator of Rho-kinase that generates a vicious cycle for ROS augmentation, affecting ECs, VSMCs, and inflammatory cell functions (Fig. 4) (94, 97).

Rho-Kinase and Arteriosclerosis/Restenosis

As mentioned above, Rho-kinase plays a crucial role in the ROS augmentation and vascular inflammation. ROS have been implicated in the pathogenesis of neointima formation in part by promoting VSMC growth (8, 84) and by stimulating pro-


inflammatory events (40, 59, 62, 87). Accumulating evidence indicates that Rho-kinase inhibitors have broad pharmacological properties (111, 115, 117). The beneficial effects of the long-term inhibition of Rho-kinase for the treatment of cardiovascular disease have been demonstrated in various animal models, such as coronary vasospasm, arteriosclerosis, restenosis, ischemia-reperfusion injury, hypertension, pulmonary hypertension, stroke, and cardiac hypertrophy/heart failure (111, 115, 117). Gene transfer of dominant-negative Rho-kinase reduced the neointimal formation in pigs (24). Long-term treatment with a Rho-kinase inhibitor suppressed neointima formation after vascular injury in vivo (101, 105), monocyte chemoattractant protein-1-induced vascular lesion formation (72), constrictive remodeling (113, 114), in-stent restenosis (70) and the development of cardiac allograft vasculopathy (36).

Arteriosclerosis is a slowly progressing inflammatory process of the arterial wall that involves the intima, media, and adventitia (111, 117). Accumulating evidence indicates that Rho-kinase-mediated pathway is substantially involved in EC dysfunction (125, 134), VSMC contraction (46), VSMC proliferation and migration in the media (143), and accumulation of inflammatory cells in the adventitia (72). Those Rho-kinase-mediated cellular responses led to the development of vascular disease. In fact, the mRNA expression of ROCKs is enhanced in the inflammatory and arteriosclerotic arterial lesions in animals (46) and humans (48). In the context of atherosclerosis, Rho-kinase should be regarded as a proinflammatory and proatherogenic molecule. Thus Rho-kinase is an important new therapeutic target for the treatment of atherosclerosis.

Rho-Kinase and Coronary Vasospasm

It has been demonstrated that Rho-kinase is substantially involved in the pathogenesis of coronary vasospasm. Coronary vasospasm plays an important role in variant angina, myocardial infarction, and sudden death (121). It was demonstrated that the serum level of cortisol, one of the important stress hormones,

Fig. 4. Roles of the Rho-kinase/CyPA system. CyPA is secreted from VSMCs through a process requiring Rho-kinase activity and generates a vicious cycle for ROS augmentation. Extracellular CyPA induces Rho-kinase activation. CyPA and Rho-kinase augment ROS production and promote VSMC proliferation/migration, inflammation, matrix metalloproteinase (MMP) activation, endothelial dysfunction, endothelial nitric oxide synthase downregulation, and adhesion molecules expression. EC, endothelial cell.



causes coronary hyperreactivity through the activation of Rho-kinase in pigs *in vivo* (39). The activity and the expression of ROCKs are enhanced at the inflammatory/arteriosclerotic coronary lesions (47). Accumulating evidence indicates that Rho-kinase plays a crucial role in the pathogenesis of coronary vasospasm. Intracoronary administration of fasudil (49) and of hydroxyfasudil (116) inhibited coronary spasm in pigs *in vivo* (113). We have demonstrated that fasudil is effective in preventing coronary vasospasm and resultant myocardial ischemia in patients with vasospastic angina (68). Thus fasudil is useful for the treatment of ischemic coronary syndromes caused by coronary artery spasm. Fasudil is also effective in treating patients with microvascular angina (73). The clinical trials of the effects of fasudil in Japanese patients with stable effort angina demonstrated that the long-term oral treatment with the Rho-kinase inhibitor is effective in ameliorating exercise tolerance in those patients (112). We also have recently demonstrated that Rho-kinase activity in circulating neutrophils is a useful biomarker for the diagnosis and disease activity assessment in patients with vasospastic angina (51).

Rho-Kinase and Myocardial Ischemia-Reperfusion Injury

ROS production and Rho-kinase activation play a crucial role in myocardial damage after ischemia-reperfusion. We have demonstrated that pretreatment with fasudil before reperfusion prevents endothelial dysfunction and reduces the extent of myocardial infarction in dogs *in vivo* (142). The beneficial effect of fasudil has been also demonstrated in a rabbit model of myocardial ischemia induced by an intravenous administration of endothelin-1 (89), a canine model of pacing-induced myocardial ischemia (132), and a rat model of vasopressin-induced chronic myocardial ischemia (98).

Rho-Kinase and Aortic Aneurysms

Aortic aneurysm is formed by chronic inflammation of the aortic wall, associated with decreased medial VSMCs and progressive destruction of structural components, particularly the elastic lamina (63). Key mechanisms include VSMC senescence (57), oxidative stress (31, 127), increased local production of proinflammatory cytokines (13), and increased activities of MMPs that degrade extracellular matrix (119, 145). Chronic ANG II infusion into apolipoprotein E-deficient mice promotes aortic aneurysm formation (17, 18). In animal models of aortic aneurysm, the genetic and pharmacological inhibition of ROS production (29, 128) and MMPs (67, 129) suppressed the development of aneurysms. A chronic inhibition of Rho-kinase by fasudil has been reported to reduce ANG II-induced aortic aneurysm formation (140). The activation of Rho-kinase promotes CyPA secretion from VSMCs and extracellular CyPA stimulates VSMC migration, proliferation, and MMP activation (45, 60) (Fig. 4). Extracellular CyPA is also a chemoattractant for inflammatory cells (45, 50, 120) and further activates vascular Rho-kinase (Fig. 4). Recently, we have demonstrated that CyPA augments ANG II-induced ROS production, MMP activation, and inflammatory cell recruitment into the aortic VSMCs, contributing to the aortic aneurysm formation (95). CyPA is highly expressed in the aorta of patients with aortic aneurysm (95). Our findings suggest that Rho-kinase/CyPA signaling pathway is a novel therapeutic

target for aortic aneurysm. All these data are a proof of concept that both Rho-kinase and CyPA play a crucial role in VSMCs by augmenting ROS generation. ANG II induces Rho-kinase activation and promotes CyPA secretion (Fig. 3). Secreted extracellular CyPA augments Rho-kinase activity in a synergistic manner (91) (Fig. 4). Secreted CyPA, acting as a proinflammatory cytokine, then synergistically augments ANG II-mediated ROS production, contributing to the onset of vascular inflammatory cell migration and aortic aneurysm formation (128, 141).

Rho-Kinase, Cardiac Hypertrophy, and Heart Failure

ANG II plays a key role in many physiological and pathological processes in cardiac cells, including cardiac hypertrophy (71). Understanding the molecular mechanisms for ANG II-induced myocardial disorders is important to develop new therapies for cardiac dysfunction (88). One important mechanism now recognized to be involved in ANG II-induced cardiac hypertrophy is ROS production (3, 76); however, the precise mechanism by which ROS cause myocardial hypertrophy and dysfunction still remains to be fully elucidated (106). It has been demonstrated that cardiac troponin is a substrate of Rho-kinase (133). Rho-kinase phosphorylates troponin and inhibits tension generation in cardiac myocytes. We have recently demonstrated that Rho-kinase inhibition with fasudil suppresses the development of cardiac hypertrophy and diastolic heart failure in Dahl salt-sensitive rats (26). Furthermore, our recent study provides strong mechanistic evidence of synergy between CyPA and Rho-kinase to increase ROS generation (95). Since ROS stimulates myocardial hypertrophy, matrix remodeling, and cellular dysfunction (126), Rho-kinase and CyPA may work together to promote ROS production and ANG II-induced cardiac hypertrophy (Fig. 4). In fact, CyPA was required for ANG II-mediated cardiac hypertrophy by directly potentiating ROS production, stimulating proliferation and migration of cardiac fibroblasts, and promoting cardiac myocyte hypertrophy in mice (96). In patients with heart failure, intra-arterial infusion of fasudil caused a preferential increase in forearm blood flow compared with that in control subjects, suggesting an involvement of Rho-kinase in the increased peripheral vascular resistance in patients with heart failure (55).

Rho-Kinase and Hypertension

Short-term administration of Y-27632, another Rho-kinase inhibitor, preferentially reduces systemic blood pressure in a dose-dependent manner in rat models of systemic hypertension, suggesting an involvement of Rho-kinase in the pathogenesis of hypertension (131). The expression of Rho-kinase was significantly increased in spontaneously hypertensive rats (74). Rho-kinase may be also involved in the central mechanisms of sympathetic nerve activity (41, 42).

Rho-Kinase and Pulmonary Hypertension

Pulmonary hypertension is associated with hypoxic exposure, endothelial dysfunction, VSMC hypercontraction and proliferation, enhanced ROS production, and inflammatory cell migration, for which Rho-kinase may also be substantially involved. Indeed, a long-term treatment with fasudil suppresses the development of monocrotaline-induced pulmonary hyper-

tension in rats (1) and of hypoxia-induced pulmonary hypertension in mice (2). Recently, we were able to obtain direct evidence for Rho-kinase activation in patients with pulmonary arterial hypertension (PAH) (22). Because the secretion of CyPA is regulated by Rho-kinase (95, 120), we tested the hypothesis that CyPA contributes to Rho-kinase activation and pulmonary vascular remodeling in PAH patients and noted enhanced CyPA expression on the α -smooth muscle actin-positive cells in the lung from patients with PAH (91). Additionally, statins and Rho-kinase inhibitor reduced the secretion of CyPA from VSMCs (95, 120) and pravastatin ameliorated hypoxia-induced pulmonary hypertension in mice (90, 92). Thus it is possible that the inhibition of CyPA secretion by statins (90) or Rho-kinase inhibitors (1, 43) may contribute to the therapeutic effects of these drugs on pulmonary hypertension. It has been reported that an intravenous injection of a number of chemically different Rho-kinase inhibitors reduces systemic and pulmonary arterial pressures under resting baseline tone conditions (9, 14, 20, 21). These data suggest that Rho-kinase plays a physiological role in the maintenance of baseline vasoconstrictor tone in the pulmonary and systemic vascular beds. Furthermore, intravenous infusion of fasudil significantly reduced pulmonary vascular resistance in patients with PAH, indicating an involvement of Rho-kinase in the pathogenesis of PAH in humans (27). Therefore, fasudil will decrease pulmonary arterial pressure in any situation in which vasoconstrictor tone is increased in the pulmonary vascular bed. A most important point in clinical settings is the chronic effects of the drugs (Fig. 4). The effects of long-acting fasudil in patients with PAH are now under investigation.

Conclusion

The identification of Rho-kinase as a mediator of cardiovascular diseases associated with inflammation and oxidative stress provides insight into the development of new therapies. Accumulating evidence suggests that Rho-kinase is substantially involved in the pathogenesis of a variety of cardiovascular diseases and that Rho-kinase inhibitors are useful for the treatment of those cardiovascular diseases. Clinical studies with fasudil have suggested that the Rho-kinase inhibitor may be useful for the treatment of a wide range of cardiovascular diseases, as mentioned in this article. Importantly, Rho-kinase inhibitors and statins significantly reduce CyPA secretion from VSMCs in animals. Blocking the malignant cycle that augments ROS production through CyPA secretion may be partially involved in the beneficial effect of Rho-kinase inhibitors. In conclusion, accumulating experimental and clinical evidence indicates that Rho-kinase is an important new target for the treatment of cardiovascular disease.

GRANTS

This work was supported by Japanese Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid 08107961, 08107961, 08101562, 09006924, and 10002019 and Japanese Ministry of Health, Labour, and Welfare Grants-in-Aid for Scientific Research (Tokyo, Japan) 08005713, 09158526, and 10102895 and grants-in-aid for scientific research on innovative areas (research in a proposed research area), MEXT, Japan.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the author(s).

REFERENCES

1. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. *Circ Res* 94: 385–393, 2004.
2. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, Kaibuchi K, Shimokawa H. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. *J Cardiovasc Pharmacol* 48: 280–285, 2006.
3. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM. NADPH oxidase signaling and cardiac myocyte function. *J Mol Cell Cardiol* 47: 15–22, 2009.
4. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis Oxidative stress and the mediation of arterial inflammatory response: a new perspective. *Hypertension* 25: 155–161, 1995.
5. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, Kaibuchi K. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. *Science* 275: 1308–1311, 1997.
6. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). *J Biol Chem* 271: 20246–20249, 1996.
7. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M, Hidaka H. Mechanism of action of a novel antivasospasm drug, HA1077. *J Pharmacol Exp Ther* 241: 1033–1040, 1987.
8. Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by H_2O_2 and O_2^- in vascular smooth muscle cells. *Circ Res* 77: 29–36, 1995.
9. Badejo AM Jr, Dhaliwal JS, Casey DB, Gallen TB, Greco AJ, Kadowitz PJ. Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat. *Am J Physiol Lung Cell Mol Physiol* 295: L828–L836, 2008.
10. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. *Physiol Rev* 81: 999–1030, 2001.
11. Berk BC, Alexander RW, Brock TA, Gimbrone MA Jr, Webb RC. Vasoconstriction: a new activity for platelet-derived growth factor. *Science* 232: 87–90, 1986.
12. Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. *Biochim Biophys Acta* 1603: 47–82, 2003.
13. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. *J Clin Invest* 112: 1318–1331, 2003.
14. Casey DB, Badejo AM, Dhaliwal JS, Sikora JL, Fokin A, Golwala NH, Greco AJ, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ. Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat. *Am J Physiol Heart Circ Physiol* 299: H184–H192, 2010.
15. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. *Nat Cell Biol* 3: 339–345, 2001.
16. Damsker JM, Bukrinsky MI, Constant SL. Preferential chemotaxis of activated human $CD4^+$ T cells by extracellular cyclophilin A. *J Leukoc Biol* 82: 613–618, 2007.
17. Daugherty A, Cassis L. Angiotensin II-mediated development of vascular diseases. *Trends Cardiovasc Med* 14: 117–120, 2004.
18. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *J Clin Invest* 105: 1605–1612, 2000.
19. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. *Biochem J* 351: 95–105, 2000.
20. Dhaliwal JS, Badejo AM Jr, Casey DB, Murthy SN, Kadowitz PJ. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin-2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. *J Pharmacol Exp Ther* 330: 334–341, 2009.
21. Dhaliwal JS, Casey DB, Greco AJ, Badejo AM Jr, Gallen TB, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ. Rho kinase and

- Ca²⁺ entry mediate increased pulmonary and systemic vascular resistance in L-NAME-treated rats. *Am J Physiol Lung Cell Mol Physiol* 293: L1306–L1313, 2007.
22. Do e Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, Tada T, Saji K, Sugimura K, Fujita H, Hoshikawa Y, Nawata J, Kondo T, Shimokawa H. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. *Circ J* 73: 1731–1739, 2009.
 23. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. *Nature* 420: 629–635, 2002.
 24. Eto Y, Shimokawa H, Hiroki J, Morishige K, Kandabashi T, Matsumoto Y, Amano M, Hoshijima M, Kaibuchi K, Takeshita A. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. *Am J Physiol Heart Circ Physiol* 278: H1744–H1750, 2000.
 25. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. *Trends Pharmacol Sci* 22: 32–39, 2001.
 26. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H. Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. *J Cardiovasc Pharmacol* 51: 317–326, 2008.
 27. Fukumoto Y, Matoba T, Ito A, Tanaka H, Kishi T, Hayashidani S, Abe K, Takeshita A, Shimokawa H. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. *Heart* 91: 391–392, 2005.
 28. Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, Takeya M, Yoshimura T, Takeshita A. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. *Hypertension* 38: 100–104, 2001.
 29. Gavazzi G, Deffert C, Trocme C, Schappi M, Herrmann FR, Krause KH. NOX1 deficiency protects from aortic dissection in response to angiotensin II. *Hypertension* 50: 189–196, 2007.
 30. Griendling KK, Berk BC, Ganz P, Gimbrone MA Jr, Alexander RW. Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the art lecture. *Hypertension* 9: III181–III185, 1987.
 31. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. *Circulation* 108: 2034–2040, 2003.
 32. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res* 74: 1141–1148, 1994.
 33. Guilluy C, Bregeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. *Nat Med* 16: 183–190, 2010.
 34. Hall A. Rho GTPases and the actin cytoskeleton. *Science* 279: 509–514, 1998.
 35. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Kaibuchi K, Takeshita A. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. *Circ Res* 94: 46–52, 2004.
 36. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. *Circulation* 109: 2234–2239, 2004.
 37. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. *Circ Res* 93: 767–775, 2003.
 38. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. *J Mol Cell Cardiol* 37: 537–546, 2004.
 39. Hizume T, Morikawa K, Takaki A, Abe K, Sunagawa K, Amano M, Kaibuchi K, Kubo C, Shimokawa H. Sustained elevation of serum cortisol level causes sensitization of coronary vasoconstricting responses in pigs in vivo: a possible link between stress and coronary vasospasm. *Circ Res* 99: 767–775, 2006.
 40. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. *Circ J* 73: 615–621, 2009.
 41. Ito K, Hirooka Y, Kishi T, Kimura Y, Kaibuchi K, Shimokawa H, Takeshita A. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. *Hypertension* 43: 156–162, 2004.
 42. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, Takeshita A. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. *Circ Res* 92: 1337–1343, 2003.
 43. Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, Yutani C, Yamagishi M, Kimura H, Kangawa K. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. *Am J Respir Crit Care Med* 170: 1204–1211, 2004.
 44. Jin ZG, Lungu AO, Xie L, Wang M, Wong C, Berk BC. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. *Arterioscler Thromb Vasc Biol* 24: 1186–1191, 2004.
 45. Jin ZG, Melaragno MG, Liao DF, Yan C, Haendeler J, Suh YA, Lambeth JD, Berk BC. Cyclophilin A is a secreted growth factor induced by oxidative stress. *Circ Res* 87: 789–796, 2000.
 46. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Eto Y, Morishige K, Matsumoto Y, Obara K, Nakayama K, Takahashi S, Takeshita A. Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. *Arterioscler Thromb Vasc Biol* 23: 2209–2214, 2003.
 47. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, Higo T, Egashira K, Takahashi S, Kaibuchi K, Takeshita A. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. *Circulation* 101: 1319–1323, 2000.
 48. Kandabashi T, Shimokawa H, Mukai Y, Matoba T, Kunihiro I, Morikawa K, Ito M, Takahashi S, Kaibuchi K, Takeshita A. Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. *Arterioscler Thromb Vasc Biol* 22: 243–248, 2002.
 49. Katsumata N, Shimokawa H, Seto M, Kozai T, Yamawaki T, Kuwata K, Egashira K, Ikegaki I, Asano T, Sasaki Y, Takeshita A. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1beta. *Circulation* 96: 4357–4363, 1997.
 50. Khromykh LM, Kulikova NL, Anfalova TV, Muranova TA, Abramov VM, Vasiliev AM, Khlebnikov VS, Kazansky DB. Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. *Cell Immunol* 249: 46–53, 2007.
 51. Kikuchi Y, Yasuda S, Aizawa K, Tsuburaya R, Ito Y, Takeda M, Nakayama M, Ito K, Takahashi J, Shimokawa H. Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina—Possible biomarker for diagnosis and disease activity assessment. *J Am Coll Cardiol*. In press.
 52. Kim H, Kim WJ, Jeon ST, Koh EM, Cha HS, Ahn KS, Lee WH. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. *Clin Immunol* 116: 217–224, 2005.
 53. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science* 273: 245–248, 1996.
 54. Kishi H, Bao J, Kohama K. Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. *J Biochem* 128: 719–722, 2000.
 55. Kishi T, Hirooka Y, Masumoto A, Ito K, Kimura Y, Inokuchi K, Tagawa T, Shimokawa H, Takeshita A, Sunagawa K. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. *Circulation* 111: 2741–2747, 2005.
 56. Komander D, Garg R, Wan PT, Ridley AJ, Barford D. Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure. *EMBO J* 27: 3175–3185, 2008.
 57. Kunieda T, Minamoto T, Nishi J, Tateno K, Oyama T, Katsuno T, Miyauchi H, Orimo M, Okada S, Takamura M, Nagai T, Kaneko S, Komuro I. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. *Circulation* 114: 953–960, 2006.

58. **Leung T, Manser E, Tan L, Lim L.** A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. *J Biol Chem* 270: 29051–29054, 1995.
59. **Li M, Fukagawa NK.** Age-related changes in redox signaling and VSMC function. *Antioxid Redox Signal* 12: 641–655.
60. **Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R, Berk BC.** Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. *J Biol Chem* 275: 189–196, 2000.
61. **Liao JK, Seto M, Noma K.** Rho kinase (ROCK) inhibitors. *J Cardiovasc Pharmacol* 50: 17–24, 2007.
62. **Libby P.** Inflammation in atherosclerosis. *Nature* 420: 868–874, 2002.
63. **Libby P, Okamoto Y, Rocha VZ, Folco E.** Inflammation in atherosclerosis: transition from theory to practice. *Circ J* 74: 213–220, 2010.
64. **Loirand G, Guerin P, Pacaud P.** Rho kinases in cardiovascular physiology and pathophysiology. *Circ Res* 98: 322–334, 2006.
65. **Loirand G, Pacaud P.** The role of Rho protein signaling in hypertension. *Nat Rev Cardiol* 7: 637–647, 2010.
66. **Mackay DJ, Hall A.** Rho GTPases. *J Biol Chem* 273: 20685–20688, 1998.
67. **Manning MW, Cassis LA, Daugherty A.** Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol* 23: 483–488, 2003.
68. **Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A.** Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. *Circulation* 105: 1545–1547, 2002.
69. **Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K.** Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. *EMBO J* 15: 2208–2216, 1996.
70. **Matsumoto Y, Uwatoku T, Oi K, Abe K, Hattori T, Morishige K, Eto Y, Fukumoto Y, Nakamura K, Shibata Y, Matsuda T, Takeshita A, Shimokawa H.** Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. *Arterioscler Thromb Vasc Biol* 24: 181–186, 2004.
71. **Mehta PK, Griendling KK.** Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. *Am J Physiol Cell Physiol* 292: C82–C97, 2007.
72. **Miyata K, Shimokawa H, Kandabashi T, Higo T, Morishige K, Eto Y, Egashira K, Kaibuchi K, Takeshita A.** Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. *Arterioscler Thromb Vasc Biol* 20: 2351–2358, 2000.
73. **Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A.** Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. *J Am Coll Cardiol* 41: 15–19, 2003.
74. **Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A.** Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. *FASEB J* 15: 1062–1064, 2001.
75. **Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S.** ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. *FEBS Lett* 392: 189–193, 1996.
76. **Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M.** Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor- α and angiotensin II. *Circulation* 98: 794–799, 1998.
77. **Neco P, Giner D, Viniegra S, Borges R, Villarreal A, Gutierrez LM.** New roles of myosin II during vesicle transport and fusion in chromaffin cells. *J Biol Chem* 279: 27450–27457, 2004.
78. **Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, Abe J, Alexis JD, Sparks JD, Berk BC.** Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. *J Exp Med* 208: 53–66, 2011.
79. **Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Lusinskas FW, Sun J, Liao JK.** ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. *J Clin Invest* 118: 1632–1644, 2008.
80. **Oi K, Shimokawa H, Hiroki J, Uwatoku T, Abe K, Matsumoto Y, Nakajima Y, Nakajima K, Takeichi S, Takeshita A.** Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. *Arterioscler Thromb Vasc Biol* 24: 918–922, 2004.
81. **Olofsson B.** Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. *Cell Signal* 11: 545–554, 1999.
82. **Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, Wolin MS.** Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. *Circ Res* 69: 601–608, 1991.
83. **Radeff JM, Nagy Z, Stern PH.** Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C α translocation and IL-6 promoter activity in osteoblastic cells. *J Bone Miner Res* 19: 1882–1891, 2004.
84. **Rao GN, Berk BC.** Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. *Circ Res* 70: 593–599, 1992.
85. **Riento K, Guasch RM, Garg R, Jin B, Ridley AJ.** RhoE binds to ROCK I and inhibits downstream signaling. *Mol Cell Biol* 23: 4219–4229, 2003.
86. **Riento K, Ridley AJ.** Rocks: multifunctional kinases in cell behaviour. *Nat Rev Mol Cell Biol* 4: 446–456, 2003.
87. **Ross R.** Atherosclerosis is an inflammatory disease. *Am Heart J* 138: S419–S420, 1999.
88. **Sadoshima J, Xu Y, Slayter HS, Izumo S.** Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. *Cell* 75: 977–984, 1993.
89. **Sato S, Ikegaki I, Asano T, Shimokawa H.** Antiischemic properties of fasudil in experimental models of vasospastic angina. *Jpn J Pharmacol* 87: 34–40, 2001.
90. **Satoh K, Fukumoto Y, Nakano M, Sugimura K, Nawata J, Demachi J, Karibe A, Kagaya Y, Ishii N, Sugamura K, Shimokawa H.** Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. *Cardiovasc Res* 81: 226–234, 2009.
91. **Satoh K, Fukumoto Y, Sugimura K, Tatebe S, Miura Y, Miyamichi S, Nakamura K, Nigro P, Berk BC, Shimokawa H.** Cyclophilin A mediates pulmonary vascular remodeling by rho-kinase activation in patients with pulmonary hypertension. *Circulation* 122, Suppl: A11001, 2010.
92. **Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, Karibe A, Minegishi N, Suzuki N, Yamamoto M, Ono M, Watanabe J, Shirato K, Ishii N, Sugamura K, Shimokawa H.** Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. *Circulation* 113: 1442–1450, 2006.
93. **Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, Mohan A, Pan S, Li L, Jin ZG, Yan C, Abe J, Berk BC.** Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. *Circulation* 117: 3088–3098, 2008.
94. **Satoh K, Nigro P, Berk BC.** Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. *Antioxid Redox Signal* 12: 675–682, 2010.
95. **Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J, Illig KA, Berk BC.** Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. *Nat Med* 15: 649–656, 2009.
96. **Satoh K, Nigro P, Zeidan A, Soe NN, Jaffre F, Oikawa M, O'Dell MR, Cui Z, Menon P, Lu Y, Mohan A, Yan C, Blaxall BC, Berk BC.** Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 31: 1116–1123, 2011.
97. **Satoh K, Shimokawa H, Berk BC.** Cyclophilin A: promising new target in cardiovascular therapy. *Circ J* 74: 2249–2256, 2010.
98. **Satoh S, Ikegaki I, Toshima Y, Watanabe A, Asano T, Shimokawa H.** Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats. *Life Sci* 72: 103–111, 2002.
99. **Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Vaillant N, Gadeau AP, Desgranges C, Scalbert E, Chardin P, Pacaud P, Loirand G.** P2Y₁, P2Y₂, P2Y₄, and P2Y₆ receptors are coupled to Rho and Rho kinase activation in vascular myocytes. *Am J Physiol Heart Circ Physiol* 278: H1751–H1761, 2000.
100. **Sauzeau V, Le Mellionec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G.** Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. *Circ Res* 88: 1102–1104, 2001.

101. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. *Circulation* 101: 2030–2033, 2000.
102. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. *Genes Dev* 16: 1587–1609, 2002.
103. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. *Circ Res* 84: 1186–1193, 1999.
104. Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breard J. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. *J Exp Med* 201: 465–471, 2005.
105. Shibata R, Kai H, Seki Y, Kato S, Morimatsu M, Kaibuchi K, Imaizumi T. Role of Rho-associated kinase in neointima formation after vascular injury. *Circulation* 103: 284–289, 2001.
106. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. *Circ J* 73: 608–614, 2009.
107. Shimizu T, Satoh K, Tanaka S, Fukumoto Y, Shimokawa H. ROCK2 in vascular smooth muscle cells plays a crucial role for hypoxia-induced pulmonary hypertension in mice (Abstract). *Circulation* 122: A16516, 2010.
108. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, Oshima M, Noda Y, Matsumura F, Taketo MM, Narumiya S. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. *J Cell Biol* 168: 941–953, 2005.
109. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. *Jpn Circ J* 64: 1–12, 2000.
110. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. *J Mol Cell Cardiol* 31: 23–37, 1999.
111. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. *J Cardiovasc Pharmacol* 39: 319–327, 2002.
112. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. *J Cardiovasc Pharmacol* 40: 751–761, 2002.
113. Shimokawa H, Ito A, Fukumoto Y, Kadokami T, Nakaike R, Sakata M, Takayanagi T, Egashira K, Takeshita A. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. *J Clin Invest* 97: 769–776, 1996.
114. Shimokawa H, Morishige K, Miyata K, Kandabashi T, Eto Y, Ikegaki I, Asano T, Kaibuchi K, Takeshita A. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. *Cardiovasc Res* 51: 169–177, 2001.
115. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. *Trends Pharmacol Sci* 28: 296–302, 2007.
116. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. *Cardiovasc Res* 43: 1029–1039, 1999.
117. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. *Arterioscler Thromb Vasc Biol* 25: 1767–1775, 2005.
118. Shimokawa H, Tomoike H, Nabeyama S, Yamamoto H, Araki H, Nakamura M, Ishii Y, Tanaka K. Coronary artery spasm induced in atherosclerotic miniature swine. *Science* 221: 560–562, 1983.
119. Sun J, Sukhova GK, Yang M, Wolters PJ, MacFarlane LA, Libby P, Sun C, Zhang Y, Liu J, Ennis TL, Knispel R, Xiong W, Thompson RW, Baxter BT, Shi GP. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. *J Clin Invest* 117: 3359–3368, 2007.
120. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. *Circ Res* 98: 811–817, 2006.
121. Takagi Y, Yasuda S, Takahashi J, Takeda M, Nakayama M, Ito K, Hirose M, Wakayama Y, Fukuda K, Shimokawa H. Importance of dual induction tests for coronary vasospasm and ventricular fibrillation in patients surviving out-of-hospital cardiac arrest. *Circ J* 73: 767–769, 2009.
122. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. *Physiol Rev* 81: 153–208, 2001.
123. Takeda K, Ichiki T, Tokunou T, Iino N, Fujii S, Kitabatake A, Shimokawa H, Takeshita A. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. *Arterioscler Thromb Vasc Biol* 21: 868–873, 2001.
124. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. *Arterioscler Thromb Vasc Biol* 21: 1712–1719, 2001.
125. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. *Circulation* 106: 57–62, 2002.
126. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. *Hypertension* 49: 241–248, 2007.
127. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. *Hypertension* 42: 1075–1081, 2003.
128. Thomas M, Gavrila D, McCormick ML, Miller FJ, Jr, Daugherty A, Cassis LA, Dellsperger KC, Weintraub NL. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. *Circulation* 114: 404–413, 2006.
129. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. *Ann NY Acad Sci* 878: 159–178, 1999.
130. Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo MM, Narumiya S. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. *Mol Cell Biol* 23: 5043–5055, 2003.
131. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. *Nature* 389: 990–994, 1997.
132. Utsunomiya T, Satoh S, Ikegaki I, Toshima Y, Asano T, Shimokawa H. Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. *Br J Pharmacol* 134: 1724–1730, 2001.
133. Vahebi S, Kobayashi T, Warren CM, de Tombe PP, Solaro RJ. Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. *Circ Res* 96: 740–747, 2005.
134. van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, van Hinsbergh VW. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. *Circ Res* 87: 335–340, 2000.
135. Vanhoutte PM. Endothelium-derived free radicals: for worse and for better. *J Clin Invest* 107: 23–25, 2001.
136. Wang F, Okamoto Y, Inoki I, Yoshioka K, Du W, Qi X, Takuwa N, Gonda K, Yamamoto Y, Ohkawa R, Nishiuchi T, Sugimoto N, Yatomi Y, Mitsumori K, Asano M, Kinoshita M, Takuwa Y. Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. *J Clin Invest* 120: 3979–3995, 2010.
137. Wang J, Weigand L, Foxson J, Shimoda LA, Sylvester JT. Ca²⁺ signaling in hypoxic pulmonary vasoconstriction: effects of myosin light chain and Rho kinase antagonists. *Am J Physiol Lung Cell Mol Physiol* 293: L674–L685, 2007.
138. Wang L, Wang CH, Jia JF, Ma XK, Li Y, Zhu HB, Tang H, Chen ZN, Zhu P. Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis. *J Clin Immunol* 30: 24–33, 2010.
139. Wang Y, Zheng XR, Riddick N, Bryden M, Baur W, Zhang X, Surks HK. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. *Circ Res* 104: 531–540, 2009.
140. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, Halks-Miller M, Mahmoudi M, Schroeder M, Subramanyam B, Tseng JL, Deng GD, Schirm S, Johns A, Kausar K, Dole WP, Light DR. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. *Circulation* 111: 2219–2226, 2005.
141. Weintraub NL. Understanding abdominal aortic aneurysm. *N Engl J Med* 361: 1114–1116, 2009.
142. Yada T, Shimokawa H, Hiramatsu O, Kajita T, Shigeto F, Tanaka E, Shinozaki Y, Mori H, Kiyooka T, Katsura M, Ohkuma S, Goto M, Ogasawara Y, Kajiya F. Beneficial effect of hydroxyfasudil, a

- specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. *J Am Coll Cardiol* 45: 599–607, 2005.
143. **Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T.** Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. *Hypertension* 35: 313–318, 2000.
144. **Yang Y, Lu N, Zhou J, Chen ZN, Zhu P.** Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. *Rheumatology (Oxford)* 47: 1299–1310, 2008.
145. **Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M.** Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. *Nat Med* 11: 1330–1338, 2005.
146. **Zhou Q, Gensch C, Liao JK.** Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. *Trends Pharmacol Sci* 32: 167–173, 2011.

